<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111917</url>
  </required_header>
  <id_info>
    <org_study_id>NJ202</org_study_id>
    <secondary_id>1UL1RR025780</secondary_id>
    <nct_id>NCT00111917</nct_id>
  </id_info>
  <brief_title>Beryllium Infliximab Study: Clinical Interventional Trial</brief_title>
  <acronym>BISCIT</acronym>
  <official_title>Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maier, Lisa, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Maier, Lisa, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to test the clinical effectiveness of a drug called
      infliximab (Remicade) in chronic beryllium disease (CBD). This drug may reduce tumor necrosis
      factor-alpha (TNF-a), which is associated with more severe disease and inflammation in the
      lung. Receiving infliximab may help with symptoms, and may improve clinical testing data
      normally ordered by your doctor, such as breathing tests. Baseline and follow-up testing will
      look for improvements in breathing tests (pulmonary function testing), exchange of oxygen in
      the lungs (exercise test), chest x ray, and lung inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:

      The central hypothesis of this study is that infliximab will prove to be efficacious in the
      treatment of chronic beryllium disease (CBD), and that it will do so by inhibiting beryllium
      specific T cell proliferation and cytokine production.

      Specific Aims:

      Specific Aim 1: To determine the clinical effectiveness of infliximab on chronic beryllium
      disease. The efficacy of infliximab will be measured by improvement in arterial gas exchange,
      or arterial alveolar oxygen gradient (A-ad02) at end exercise in subjects with CBD who remain
      symptomatic and with pulmonary impairment despite current treatment with prednisone and/or
      methotrexate. Secondary outcome measures will include change in airflow, lung volume,
      diffusing capacity (DLCO), profusion of small opacities on chest x-ray, dyspnea score, and
      quality of life questionnaires.

      Specific Aim 2: To determine the effect of infliximab on intermediate markers of biological
      function in CBD. In vitro studies will examine the effect of infliximab on blood and lung
      cells in culture, as measured by a decrease in beryllium (Be)-stimulated lymphocyte
      proliferation; a decrease in Be-stimulated cytokine production, including TNF-a, IFN-g, and
      IL-2; altered Be-stimulated apoptosis of macrophages or lymphocytes.

      Research Design and Methods: Since no information is available regarding the pharmacokinetics
      of infliximab in patients with CBD, the pharmacokinetic information available from the use of
      infliximab in other similar inflammatory conditions formed the basis for selecting the dose
      regimen for this protocol. Particularly, a 5mg/kg dose will be used for this study, based on
      the dose selection used in the sarcoidosis protocol C0168T48 presently underway in a
      multi-center trial (NJC IRB HS-1771).

      This is an investigator initiated, 40 week, randomized, double-blind, placebo controlled
      study to evaluate the efficacy of infliximab dosed at 5mg/kg, compared to placebo, in
      individuals with symptomatic CBD with pulmonary involvement despite prednisone and/or
      methotrexate treatment. Infliximab or placebo will be infused at weeks 0, 2, 6, 12, 18, and
      24 including spirometry, lung volumes and DLCO. Approximately 20 participants will be
      enrolled in the study at National Jewish Medical and Research Center at a 3:1 drug: placebo
      rate.

      The primary endpoint of this study will be a change from baseline testing to week 28 testing
      in the A-adO2 at end exercise on a 6 minute walk. At baseline evaluation, subjects will
      undergo full pulmonary function testing, a blood draw for the beryllium lymphocyte
      proliferation test (BeLPT), 6 minute walk, chest x-ray, and quality of life and dyspnea
      questionnaires. Follow-up full pulmonary function testing, rest and end exercise A-ad02,
      pulse oximetry with total distance (workload) achieved on a 6 minute walk, and chest
      radiograph will be measured at week 12. Final outcome measurements (same as baseline
      testing), including bronchoscopy with BAL, will be repeated at week 28. A follow-up
      appointment will be scheduled at week 40 to assess patients' general health, as well as
      measure rest and end exercise A-ad02 and pulse oximetry with 6 minute walk, pulmonary
      function test, QOL/dyspnea scoring, and chest radiograph interstitial lung opacity profusion
      score.

      The effects of infliximab on the Be-stimulated immune response will be assessed by comparing
      the following markers before and after infliximab therapy: 1. BeLPT from blood and lavage
      cells (BAL); 2. Be-stimulated cytokine production from BAL cells including TNF-a, IFN-γ, and
      IL-2; 3. Cell-specific apoptosis. The assay will include an unstimulated control, 100 mM
      BeSO4, 100 mM Al2(SO4)3 metal-salt control, PHA - lymphocyte proliferation control,
      infliximab control, infliximab + BeSO4, infliximab + Al2(SO4)3. At days 4, 5, and 6 after Be
      exposure, the wells are pulsed with the DNA-specific precursor, 3H-TdR, incubated for four
      hours, harvested on glass fiber filters, and liquid scintillation methods are used for
      counting. Results are reported as a stimulation index, which is a ratio of the counts per
      minute of the treatment group to the counts per minute of the unstimulated group. To
      determine the effect of infliximab on cytokine production, CBD BAL and CBD PBMC will be
      stimulated with Be for 24 hours. ELISA will be used to determine TNF-α, IFN-γ, and IL-2
      supernatant levels. After 24 hours of beryllium exposure, we will harvest supernatants and
      perform ELISA testing for TNF-α, IFN-γ, and IL-2. In order to determine if infliximab causes
      an increase in lymphocyte or macrophage apoptosis, CBD BAL cells will be cultured for 24
      hours with Be. Cells will be double stained for CD4+ (Th1) and CD71+ macrophages versus
      intracellular activated caspase-3, caspase-8 and caspase-9. These in vitro studies will be
      used to assess the potential biologic function of infliximab on immune mediated diseases
      using a disease model with known antigen, CBD.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients meeting criteria to enroll in the time period
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A-a Gradient at End Exercise</measure>
    <time_frame>after 28 week follow-up. The Alveolar-arterial gradient (A-a gradient), is a measure of the difference between the alveolar partial pressure (A) of oxygen and the arterial (a) partial pressure of oxygen</time_frame>
    <description>change in end-exercise A-a gradient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Berylliosis</condition>
  <condition>Beryllium Disease</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>anti-TNF</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-80.

          -  Noncaseating granulomas and/or mononuclear cell infiltrates demonstrated on
             transbronchial lung biopsy.

          -  Abnormal blood and/or BAL BeLPT results.

          -  Current treatment with prednisone and/or methotrexate specifically for CBD and not any
             other condition, at any range of dosage, for at least 6 months prior to enrollment,
             and on a stable dosage for at least 1 month prior to first infusion.

          -  Moderate CBD severity, such that participants can safely undergo bronchoscopy with BAL
             including PaO2 &gt;= 50 mmHg on room air (at Denver altitude of 5,280 ft).

          -  Availability to come back to National Jewish Medical and Research Center for
             infusions, evaluations, and follow-ups.

          -  Capable of providing informed consent.

          -  Willing and able to adhere to the study visit schedule and other protocol-specified
             procedures.

        Exclusion Criteria:

          -  Positive tuberculosis (TB) skin test upon screening: An intradermal tuberculin skin
             test must be performed within 1 month prior to the first administration of study
             agent.

          -  Any evidence of TB.

          -  Considered ineligible according to the TB eligibility assessment, screening, and early
             detection of reactivation rules.

          -  Positive pregnancy test.

          -  Women who are pregnant, nursing, or planning pregnancy within one year after screening

          -  Contraindications to bronchoscopy and BAL such as bleeding diathesis, PaO2 &lt;50 mmHg on
             room air, evidence of acute infection, hemodynamic instability with labile blood
             pressure, either &lt;90/60 or &gt;160/110, untreated coronary artery disease, or other
             medical reason for which a subject will not be able to safely undergo bronchoscopy.

          -  Positive cultures from prior BAL indicating mycobacterial or fungal infection.

          -  Positive special stains for acid fast bacilli (AFB) or fungi on prior lung biopsies.

          -  Known atypical mycobacterium infection.

          -  Clinical evidence of active infection at time of enrollment.

          -  Serious acute infections (e.g., viral hepatitis, pneumonia or pyelonephritis) in the
             previous 3 months.

          -  Have or have had an opportunistic infection (e.g., herpes zoster [shingles],
             cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria
             other than TB) within 6 months prior to screening.

          -  Documented HIV infection.

          -  Positive serology for active hepatitis B or C. A positive result will indicate the
             need for referral to a consultant Hepatologist for further investigation and support.

          -  Use of any investigational drug within 1 month prior to screening or within 5 half
             lives of the investigational agent, whichever is longer.

          -  Treatment with any other therapeutic agent targeted at reducing TNF-a (e.g.
             pentoxifylline, thalidomide, etanercept, etc.) within 3 months of screening.

          -  Prior use of Enbrel® or Humera®.

          -  Previous administration of infliximab.

          -  Known allergy to murine (mouse) products.

          -  Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic,
             hematological, gastrointestinal, endocrine, cardiac, neurologic, or cerebral disease
             (including demyelinating diseases such as multiple sclerosis).

          -  Any history of congestive heart failure, severe right sided heart failure, or cor
             pulmonale.

          -  Presence of a transplanted organ (with the exception of a corneal transplant &gt; 3
             months prior to screening).

          -  Major surgery in the previous 3 months.

          -  Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the
             skin that has been treated with no evidence of recurrence).

          -  History of lymphoproliferative disease, including lymphoma, or signs and symptoms
             suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual
             size or location (such as nodes in the posterior triangle of the neck,
             infraclavicular, epitrochlear, or perioaortic areas), or splenomegaly.

          -  Known recent substance abuse (drug or alcohol).

          -  Poor tolerability of venipuncture or lack of adequate venous access for required blood
             sampling during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A Maier, MD,MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2005</study_first_submitted>
  <study_first_submitted_qc>May 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2005</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>September 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Beryllium Disease</keyword>
  <keyword>Berylliosis</keyword>
  <keyword>Beryllium Disease</keyword>
  <keyword>CBD</keyword>
  <keyword>Infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Berylliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We aimed to enroll 20 CBD subjects on stable doses of corticosteroids and/or methotrexate, with no evidence of active or chronic infection, malignancy, other chronic disease, or past treatment with another biologic with a 3:1 infliximab:placebo ratio</recruitment_details>
      <pre_assignment_details>the sponsor stopped the study due to slow recruitment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Infliximab</title>
          <description>This group was given an infusion of inliximab</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Placebo</title>
          <description>This group was given a placebo infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab</title>
          <description>patients who will be placed on infliximab and controls who will get placebo</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>CBD placed on placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>patient reported age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.63" lower_limit="46" upper_limit="65"/>
                    <measurement group_id="B2" value="69.75" lower_limit="67" upper_limit="74"/>
                    <measurement group_id="B3" value="56.5" lower_limit="46" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Post-Hoc</type>
        <title>Absolute Numbers of Lymphocytes</title>
        <description>Absolute number of lymphocytes*10^6/cc in blood</description>
        <time_frame>after 28 week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Infliximab infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Numbers of Lymphocytes</title>
          <description>Absolute number of lymphocytes*10^6/cc in blood</description>
          <units>absolute number*10^6/cc</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.18"/>
                    <measurement group_id="O2" value="1.02" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>A-a Gradient at End Exercise</title>
        <description>change in end-exercise A-a gradient</description>
        <time_frame>after 28 week follow-up. The Alveolar-arterial gradient (A-a gradient), is a measure of the difference between the alveolar partial pressure (A) of oxygen and the arterial (a) partial pressure of oxygen</time_frame>
        <population>Accurate measures were not obtained on all patients at both timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Infliximab infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>A-a Gradient at End Exercise</title>
          <description>change in end-exercise A-a gradient</description>
          <population>Accurate measures were not obtained on all patients at both timepoints.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="10.56"/>
                    <measurement group_id="O2" value="94.17" spread="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>BAL WBC/cc</title>
        <description>WBC * 10^6/cc in bronchalveolar lavage</description>
        <time_frame>after 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Infliximab received</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo received</description>
          </group>
        </group_list>
        <measure>
          <title>BAL WBC/cc</title>
          <description>WBC * 10^6/cc in bronchalveolar lavage</description>
          <units>absolute WBC*10^6/cc</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.04"/>
                    <measurement group_id="O2" value="0.25" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>BAL % Lymphocytes</title>
        <description>% of WBCs that are lymphocytes in bronchoalveolar lavage</description>
        <time_frame>after 28 week infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Infliximab</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Placebo received</description>
          </group>
        </group_list>
        <measure>
          <title>BAL % Lymphocytes</title>
          <description>% of WBCs that are lymphocytes in bronchoalveolar lavage</description>
          <units>percentage of lymphocytes in BAL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="7.84"/>
                    <measurement group_id="O2" value="14.7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through week 40</time_frame>
      <desc>adverse events reported through week 40</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Infliximab</title>
          <description>Infliximab infusion received</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Placebo</title>
          <description>Placebo infusion received</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>liver function levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although our goal was 20 CBD subjects, only 11 subjects were enrolled, 8:3 in the infliximab:placebo treatment arms as the study was stopped by the sponsor due to slow recruitment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Maier, MD</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>303-398-1983</phone>
      <email>maierl@njhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

